Displaying drugs 626 - 650 of 11578 in total
Tiaprofenic acid
Tiaprofenic acid is a non-steroidal anti-inflammatory drug employed in the treatment of pain, particularly arthritis pain. It belongs to the arylpropionic acid (profen) group of nonsteroidal anti-inflammatory drugs (NSAIDs).
Approved
Matched Description: … Tiaprofenic acid is a non-steroidal anti-inflammatory drug employed in the treatment of pain, particularly …
Nomifensine
Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia. The approved application holder removed Merital capsules from the market on January 23, 1986. FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal...
Approved
Withdrawn
Matched Description: … FDA published a notice of its determination that Merital capsules were removed from the market for safety …
Vemurafenib
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann...
Approved
Matched Description: … Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E ... After approval, Roche in collaboration with Genentech launched a broad development program. [L1012] …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Remoxipride
Remoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Approved
Withdrawn
Omadacycline
Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent...
Approved
Investigational
Matched Description: … Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown …
Celiprolol
Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. In 2010 a clinical trial has suggested a use for this medication in the prevention of...
Approved
Investigational
Matched Description: … It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 ... In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications ... of a rare inherited disease called vascular Ehlers–Danlos syndrome. …
Halazepam
Halazepam is a benzodiazepine derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by Schering, its manufacturer, in 2009.[L6226, L6229]
Approved
Illicit
Withdrawn
Matched Description: … Halazepam is a _benzodiazepine_ derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle …
Quinethazone
Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.
Approved
Matched Description: … Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. …
Ledipasvir
Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most...
Approved
Matched Description: … Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat ... HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 ... It is effective against genotypes 1a, 1b, 4a, and 5a and with a lesser activity against genotypes 2a …
Oteracil
Oteracil is an adjunct to antineoplastic therapy, used to reduce the toxic side effects associated with chemotherapy. Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with DB09257 and DB09256 within the commercially available product "Teysuno". The main active ingredient in Teysuno is DB09256,...
Approved
Matched Description: … The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic ... By mimicking a class of compounds called "pyrimidines" that are essential components of RNA and DNA, …
Tafamidis
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
Approved
Investigational
Efalizumab
Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn...
Approved
Investigational
Withdrawn
Matched Description: … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ... ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. ... It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy …
Famtozinameran
The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). As of November 2022, it is the primary circulating variant of...
Approved
Investigational
Matched Description: … The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. …
Hexocyclium
Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. It was once available under the tradename Tral marketed by Abbvie Inc. but has been discontinued. Proton pump inhibitors like DB00338 and opiate anti-diarrheal agents like DB00836 have largely replaced the...
Approved
Matched Description: … Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment …
Glucagon
Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.[L7634,L7637,L7640,L7643,L8519] Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.[L7640,L7643]
Glucagon was granted FDA...
Approved
Matched Description: … Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit …
Acer rubrum pollen
Acer rubrum pollen is the pollen of the Acer rubrum plant. Acer rubrum pollen is mainly used in allergenic testing.
Approved
Rufinamide
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Approved
Matched Description: … Lennox-Gastuat syndrome, a form of childhood epilepsy. ... Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like …
Lidoflazine
Approved
Experimental
Vilazodone
Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622]. Vilazodone may also be associated with less sexual dysfunction and weight gain . Vilazodone was given FDA approval on January 21, 2011[L6046,A177622].
Approved
Matched Description: … Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine …
Deflazacort
Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label]
Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which...
Approved
Investigational
Matched Description: … Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular …
Lorazepam
Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Approved
Matched Description: … Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic …
Treprostinil
Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment...
Approved
Investigational
Matched Description: … Treprostinil is a stable tricyclic analogue of prostacyclin[A248770] that promotes the vasodilation of ... [L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin …
Displaying drugs 626 - 650 of 11578 in total